MA52492B1 - Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés - Google Patents
Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associésInfo
- Publication number
- MA52492B1 MA52492B1 MA52492A MA52492A MA52492B1 MA 52492 B1 MA52492 B1 MA 52492B1 MA 52492 A MA52492 A MA 52492A MA 52492 A MA52492 A MA 52492A MA 52492 B1 MA52492 B1 MA 52492B1
- Authority
- MA
- Morocco
- Prior art keywords
- rip1
- preparation
- methods
- kinase
- inhibitory compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 title abstract 2
- 102100021009 Cytochrome b-c1 complex subunit Rieske, mitochondrial Human genes 0.000 title 1
- 101000643956 Homo sapiens Cytochrome b-c1 complex subunit Rieske, mitochondrial Proteins 0.000 title 1
- 101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102100021559 KRR1 small subunit processome component homolog Human genes 0.000 abstract 3
- 101150040948 RIP1 gene Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
L'invention concerne des composés inhibiteurs de kinase, tels que des composés inhibiteurs de protéine kinase 1 interagissant avec le récepteur (rip1), ainsi que des compositions pharmaceutiques et des combinaisons comprenant de tels composés inhibiteurs. Les composés selon l'invention, les compositions pharmaceutiques et/ou les combinaisons peuvent être utilisés pour inhiber une kinase rip1 in vivo ou ex vivo, et peuvent également traiter ou prévenir une maladie ou un état pathologique associé à une kinase, en particulier une maladie ou un état pathologique associé à rip1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666452P | 2018-05-03 | 2018-05-03 | |
| PCT/US2019/030473 WO2019213445A1 (fr) | 2018-05-03 | 2019-05-02 | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52492A MA52492A (fr) | 2021-03-10 |
| MA52492B1 true MA52492B1 (fr) | 2023-09-27 |
Family
ID=66554488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52492A MA52492B1 (fr) | 2018-05-03 | 2019-05-02 | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US10975064B2 (fr) |
| EP (1) | EP3788045B1 (fr) |
| JP (1) | JP7379467B2 (fr) |
| KR (1) | KR102823195B1 (fr) |
| CN (1) | CN112384510B (fr) |
| AU (1) | AU2019262142B2 (fr) |
| BR (1) | BR112020022423A2 (fr) |
| CA (1) | CA3099018A1 (fr) |
| CL (1) | CL2020002840A1 (fr) |
| CO (1) | CO2020015153A2 (fr) |
| CR (1) | CR20200582A (fr) |
| CY (1) | CY1126152T1 (fr) |
| DK (1) | DK3788045T3 (fr) |
| DO (1) | DOP2020000197A (fr) |
| EA (1) | EA202092581A1 (fr) |
| EC (1) | ECSP20077518A (fr) |
| ES (1) | ES2947446T3 (fr) |
| FI (1) | FI3788045T3 (fr) |
| HR (1) | HRP20230909T1 (fr) |
| HU (1) | HUE062277T2 (fr) |
| IL (1) | IL278416B2 (fr) |
| JO (1) | JOP20200277A1 (fr) |
| LT (1) | LT3788045T (fr) |
| MA (1) | MA52492B1 (fr) |
| MD (1) | MD3788045T2 (fr) |
| MX (1) | MX2020011622A (fr) |
| MY (1) | MY205388A (fr) |
| PE (1) | PE20210414A1 (fr) |
| PH (1) | PH12020551848A1 (fr) |
| PL (1) | PL3788045T3 (fr) |
| PT (1) | PT3788045T (fr) |
| RS (1) | RS64418B1 (fr) |
| SG (1) | SG11202010913PA (fr) |
| SI (1) | SI3788045T1 (fr) |
| SM (1) | SMT202300203T1 (fr) |
| UA (1) | UA128160C2 (fr) |
| WO (1) | WO2019213445A1 (fr) |
| ZA (1) | ZA202007487B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3788045T3 (fi) * | 2018-05-03 | 2023-06-28 | Rigel Pharmaceuticals Inc | RIP1-inhibitorisia yhdisteitä ja samojen valmistus- ja käyttömenetelmiä |
| RS64736B1 (sr) | 2018-05-03 | 2023-11-30 | Rigel Pharmaceuticals Inc | Jedinjenja inhibitori rip1 i postupci za njihovo dobijanje i upotrebu |
| EP4025575B1 (fr) | 2019-09-06 | 2025-12-17 | Rigel Pharmaceuticals, Inc. | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation |
| US11718612B2 (en) | 2019-09-06 | 2023-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
| WO2021046407A1 (fr) | 2019-09-06 | 2021-03-11 | Rigel Pharmaceuticals, Inc. | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| CN115298184B (zh) * | 2019-11-07 | 2025-01-28 | 里格尔药品股份有限公司 | 杂环rip1抑制化合物 |
| BR112022010082A2 (pt) * | 2019-11-26 | 2022-08-30 | Univ Texas | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI840311B (zh) | 2020-07-01 | 2024-04-21 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| CN116249696B (zh) * | 2020-08-18 | 2025-07-08 | 和记黄埔医药（上海）有限公司 | 嘧啶酮类化合物及其用途 |
| TW202300490A (zh) | 2021-03-11 | 2023-01-01 | 美商雷傑製藥公司 | 雜環rip1激酶抑制劑 |
| WO2022237890A1 (fr) * | 2021-05-14 | 2022-11-17 | 中国医药研究开发中心有限公司 | Composé à cycle fusionné du type azépine et son utilisation pharmaceutique |
| CN115894489A (zh) * | 2021-09-22 | 2023-04-04 | 中国药科大学 | 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用 |
| EP4422621A4 (fr) * | 2021-10-27 | 2025-08-27 | Merck Sharp & Dohme Llc | Inhibiteurs de ripk1 spirotricycliques et leurs procédés d'utilisation |
| KR20230100646A (ko) * | 2021-12-24 | 2023-07-05 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| CN118765280A (zh) * | 2022-02-28 | 2024-10-11 | 维泰瑞隆有限公司 | Rip1调节剂、其制备及用途 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| EP0431519B1 (fr) | 1989-12-04 | 1994-06-15 | G.D. Searle & Co. | Système pour l'administration transdermale d'albutérol |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| JPH07502219A (ja) | 1991-12-18 | 1995-03-09 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 多重層型バリアー構造体 |
| EP0553769B1 (fr) | 1992-01-29 | 1996-01-03 | FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG | Raquette, en particulier raquette de tennis |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| US20090099242A1 (en) | 2007-08-15 | 2009-04-16 | Cuny Gregory D | Heterocyclic inhibitors of necroptosis |
| TWI648274B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| US20160024098A1 (en) | 2013-03-15 | 2016-01-28 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
| AU2015304851A1 (en) * | 2014-08-21 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as RIP1 kinase inhibitors as medicaments |
| CA2976172A1 (fr) | 2015-02-13 | 2016-08-18 | Glaxosmithkline Intellectual Property Development Limited | Formes cristallines de (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepine-3-yl)-4h-1,2,4-triazole-3-carboxamide |
| JP6785252B2 (ja) | 2015-07-02 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二環式ラクタム及びその使用方法 |
| DK3362449T3 (da) | 2015-10-13 | 2021-07-19 | Inst Nat Sante Rech Med | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose |
| CN108431004B (zh) | 2015-10-23 | 2021-02-12 | 武田药品工业株式会社 | 杂环化合物 |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| MY196648A (en) * | 2016-02-05 | 2023-04-27 | Denali Therapeutics Inc | Inhibitors of Receptor-Interacting Protein Kinase 1 |
| JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ． ホフマン－ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| EP3585782A1 (fr) | 2017-02-27 | 2020-01-01 | GlaxoSmithKline Intellectual Property Development Limited | Amides hétérocycliques en tant qu'inhibiteurs de kinase |
| RS64736B1 (sr) | 2018-05-03 | 2023-11-30 | Rigel Pharmaceuticals Inc | Jedinjenja inhibitori rip1 i postupci za njihovo dobijanje i upotrebu |
| FI3788045T3 (fi) | 2018-05-03 | 2023-06-28 | Rigel Pharmaceuticals Inc | RIP1-inhibitorisia yhdisteitä ja samojen valmistus- ja käyttömenetelmiä |
| AU2019296091A1 (en) | 2018-06-26 | 2021-01-21 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Cell necrosis inhibitor, preparation method therefor and use thereof |
| JP7045526B2 (ja) | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Ｒｉｐ１キナーゼを阻害する複素環状アミド及びその使用 |
| WO2021046407A1 (fr) | 2019-09-06 | 2021-03-11 | Rigel Pharmaceuticals, Inc. | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation |
| EP4025575B1 (fr) | 2019-09-06 | 2025-12-17 | Rigel Pharmaceuticals, Inc. | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation |
| CN115298184B (zh) * | 2019-11-07 | 2025-01-28 | 里格尔药品股份有限公司 | 杂环rip1抑制化合物 |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
-
2019
- 2019-05-02 FI FIEP19724662.2T patent/FI3788045T3/fi active
- 2019-05-02 MD MDE20210214T patent/MD3788045T2/ro unknown
- 2019-05-02 CA CA3099018A patent/CA3099018A1/fr active Pending
- 2019-05-02 JP JP2021510283A patent/JP7379467B2/ja active Active
- 2019-05-02 CN CN201980045150.5A patent/CN112384510B/zh active Active
- 2019-05-02 LT LTEPPCT/US2019/030473T patent/LT3788045T/lt unknown
- 2019-05-02 AU AU2019262142A patent/AU2019262142B2/en active Active
- 2019-05-02 DK DK19724662.2T patent/DK3788045T3/da active
- 2019-05-02 UA UAA202007282A patent/UA128160C2/uk unknown
- 2019-05-02 SM SM20230203T patent/SMT202300203T1/it unknown
- 2019-05-02 WO PCT/US2019/030473 patent/WO2019213445A1/fr not_active Ceased
- 2019-05-02 PT PT197246622T patent/PT3788045T/pt unknown
- 2019-05-02 MY MYPI2020005729A patent/MY205388A/en unknown
- 2019-05-02 KR KR1020207034544A patent/KR102823195B1/ko active Active
- 2019-05-02 US US16/402,103 patent/US10975064B2/en active Active
- 2019-05-02 CR CR20200582A patent/CR20200582A/es unknown
- 2019-05-02 EP EP19724662.2A patent/EP3788045B1/fr active Active
- 2019-05-02 BR BR112020022423-5A patent/BR112020022423A2/pt unknown
- 2019-05-02 HU HUE19724662A patent/HUE062277T2/hu unknown
- 2019-05-02 RS RS20230648A patent/RS64418B1/sr unknown
- 2019-05-02 IL IL278416A patent/IL278416B2/en unknown
- 2019-05-02 JO JOP/2020/0277A patent/JOP20200277A1/ar unknown
- 2019-05-02 MX MX2020011622A patent/MX2020011622A/es unknown
- 2019-05-02 PL PL19724662.2T patent/PL3788045T3/pl unknown
- 2019-05-02 SG SG11202010913PA patent/SG11202010913PA/en unknown
- 2019-05-02 MA MA52492A patent/MA52492B1/fr unknown
- 2019-05-02 EA EA202092581A patent/EA202092581A1/ru unknown
- 2019-05-02 PE PE2020001796A patent/PE20210414A1/es unknown
- 2019-05-02 ES ES19724662T patent/ES2947446T3/es active Active
- 2019-05-02 SI SI201930550T patent/SI3788045T1/sl unknown
- 2019-05-02 HR HRP20230909TT patent/HRP20230909T1/hr unknown
-
2020
- 2020-11-02 DO DO2020000197A patent/DOP2020000197A/es unknown
- 2020-11-02 CL CL2020002840A patent/CL2020002840A1/es unknown
- 2020-11-03 PH PH12020551848A patent/PH12020551848A1/en unknown
- 2020-12-01 ZA ZA2020/07487A patent/ZA202007487B/en unknown
- 2020-12-01 CO CONC2020/0015153A patent/CO2020015153A2/es unknown
- 2020-12-01 EC ECSENADI202077518A patent/ECSP20077518A/es unknown
-
2021
- 2021-03-23 US US17/210,261 patent/US11919890B2/en active Active
-
2023
- 2023-07-25 CY CY20231100349T patent/CY1126152T1/el unknown
-
2024
- 2024-02-05 US US18/432,727 patent/US20240217958A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
| MA52488B1 (fr) | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation | |
| MA34516B1 (fr) | Imidizopyridazines substituees | |
| MA30906B1 (fr) | Composes et compositions en tant quinhibiteurs des proteines kinases | |
| MA41072A1 (fr) | Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline | |
| MA29378B1 (fr) | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer | |
| MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
| MA52288B1 (fr) | Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci | |
| MA57412B1 (fr) | Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés | |
| MA42439B1 (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| MA40814A1 (fr) | Compositions pharmaceutiques pour thérapie combinée | |
| MA47447A (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
| MA46990B1 (fr) | Compositions glp-1 et ses utilisations | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA29723B1 (fr) | Composes | |
| MA32684B1 (fr) | Dérivés de picolinamide en tant qu'inhibiteurs de kinase | |
| WO2019133770A3 (fr) | Inhibiteurs de glycolate oxydase pour le traitement de maladies | |
| MY145074A (en) | Thiazolidin-4-one derivatives | |
| MA66057A1 (fr) | Analogues de rifamycine et conjugués anticorps-médicament de ceux-ci | |
| EP4008718A4 (fr) | Dérivé d'hétéroarylamidopyridinol et composition pharmaceutique le comprenant en tant que principe actif pour prévenir ou traiter une maladie auto-immune | |
| MA46611A (fr) | Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs | |
| MA32688B1 (fr) | Composes n-sulfonamido pyrazolyles polycycliques | |
| FR3063645B1 (fr) | Acefapc pour le traitement des maladies acetylcholine dependantes | |
| MA41174B1 (fr) | Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta | |
| MA32128B1 (fr) | Association entre un sel de bis-thiazolium ou l'un de ses precurseurs et l'artémisinine ou l'un de ses derives pour le traitement du paludisme severe |